Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non‑Small-Cell Lung Cancer
Durvalumab after chemoradiotherapy improves 5‑year overall survival and progression‑free survival in unresectable stage III non‑small‑cell lung cancer.
These findings support the continued use of consolidation durvalumab after chemoradiotherapy as the standard of care for patients with unresectable, stage III non‑small‑cell lung cancer.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT